185 related articles for article (PubMed ID: 35286796)
1. Risk factors for overcorrection of severe hyponatremia: a post hoc analysis of the SALSA trial.
Yang H; Yoon S; Kim EJ; Seo JW; Koo JR; Oh YK; Jo YH; Kim S; Baek SH
Kidney Res Clin Pract; 2022 May; 41(3):298-309. PubMed ID: 35286796
[TBL] [Abstract][Full Text] [Related]
2. Derivation and Validation of a Novel Risk Score to Predict Overcorrection of Severe Hyponatremia: The Severe Hyponatremia Overcorrection Risk (SHOR) Score.
Woodfine JD; Sood MM; MacMillan TE; Cavalcanti RB; van Walraven C
Clin J Am Soc Nephrol; 2019 Jul; 14(7):975-982. PubMed ID: 31189541
[TBL] [Abstract][Full Text] [Related]
3. Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial.
Baek SH; Jo YH; Ahn S; Medina-Liabres K; Oh YK; Lee JB; Kim S
JAMA Intern Med; 2021 Jan; 181(1):81-92. PubMed ID: 33104189
[TBL] [Abstract][Full Text] [Related]
4. A low initial serum sodium level is associated with an increased risk of overcorrection in patients with chronic profound hyponatremia: a retrospective cohort analysis.
Aratani S; Hara M; Nagahama M; Taki F; Futatsuyama M; Tsuruoka S; Komatsu Y
BMC Nephrol; 2017 Oct; 18(1):316. PubMed ID: 29047375
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors of overcorrection in patients presenting with severe hyponatremia to the emergency department.
Sumi H; Imai N; Shibagaki Y
Clin Exp Nephrol; 2022 Nov; 26(11):1086-1091. PubMed ID: 35870090
[TBL] [Abstract][Full Text] [Related]
6. Osmotic Demyelination Syndrome following Correction of Hyponatremia by ≤10 mEq/L per Day.
Tandukar S; Sterns RH; Rondon-Berrios H
Kidney360; 2021 Sep; 2(9):1415-1423. PubMed ID: 35373113
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan.
Kim Y; Lee N; Lee KE; Gwak HS
Eur J Clin Pharmacol; 2020 May; 76(5):723-729. PubMed ID: 32055900
[TBL] [Abstract][Full Text] [Related]
8. Treatment of symptomatic hyponatremia with hypertonic saline: a real-life observational study.
Chifu I; Gerstl A; Lengenfelder B; Schmitt D; Nagler N; Fassnacht M; Weismann D
Eur J Endocrinol; 2021 May; 184(5):647-655. PubMed ID: 33635825
[TBL] [Abstract][Full Text] [Related]
9. Overcorrection and undercorrection with fixed dosing of bolus hypertonic saline for symptomatic hyponatremia.
Pelouto A; Refardt JC; Christ-Crain M; Zandbergen AAM; Hoorn EJ
Eur J Endocrinol; 2023 Mar; 188(3):322-330. PubMed ID: 36881992
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Serum Sodium Correction Rates for Management of Hyponatremia in Hospitalized Patients.
Pham CT; Kassab HS; Johnston JP
Ann Pharmacother; 2022 Feb; 56(2):131-138. PubMed ID: 34027713
[TBL] [Abstract][Full Text] [Related]
11. Hypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremia.
Sood L; Sterns RH; Hix JK; Silver SM; Chen L
Am J Kidney Dis; 2013 Apr; 61(4):571-8. PubMed ID: 23266328
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a protocol for hypertonic saline administration in acute euvolemic symptomatic hyponatremia: A prospective observational trial.
Bhaskar E; Kumar B; Ramalakshmi S
Indian J Crit Care Med; 2010 Oct; 14(4):170-4. PubMed ID: 21572746
[TBL] [Abstract][Full Text] [Related]
13. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection.
Mohmand HK; Issa D; Ahmad Z; Cappuccio JD; Kouides RW; Sterns RH
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1110-7. PubMed ID: 17913972
[TBL] [Abstract][Full Text] [Related]
14. Osmotic demyelination as a complication of hyponatremia correction: a systematic review.
Bastos AP; Rocha PN
J Bras Nefrol; 2024; 46(1):47-55. PubMed ID: 37523718
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rapid intermittent correction compared with slow continuous correction with hypertonic saline in patients with moderately severe or severe symptomatic hyponatremia: study protocol for a randomized controlled trial (SALSA trial).
Lee A; Jo YH; Kim K; Ahn S; Oh YK; Lee H; Shin J; Chin HJ; Na KY; Lee JB; Baek SH; Kim S
Trials; 2017 Mar; 18(1):147. PubMed ID: 28356136
[TBL] [Abstract][Full Text] [Related]
16. Comparative Safety and Effectiveness of Urea and Tolvaptan for the Management of Hyponatremia.
Scalla PA; Palma SM; Dittmar E; Zamora FJ; Trimino E
J Pharm Pract; 2024 Apr; ():8971900241247617. PubMed ID: 38652561
[No Abstract] [Full Text] [Related]
17. Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan.
Hanna RM; Velez JC; Rastogi A; Nguyen MK; Kamgar MK; Moe K; Arman F; Hasnain H; Nobakht N; Selamet U; Kurtz I
Kidney Med; 2020; 2(1):20-28. PubMed ID: 32734225
[TBL] [Abstract][Full Text] [Related]
18. NaCl 3% Bolus Therapy as Emergency Treatment for Severe Hyponatremia: Comparison of 100 mL vs 250 mL.
Massop K; Haverkort DA; Bech AP; de Boer H
J Clin Endocrinol Metab; 2023 Jul; 108(8):e521-e526. PubMed ID: 36808420
[TBL] [Abstract][Full Text] [Related]
19. Treatment of symptomatic hyponatremia.
Decaux G; Soupart A
Am J Med Sci; 2003 Jul; 326(1):25-30. PubMed ID: 12861122
[TBL] [Abstract][Full Text] [Related]
20. Association of intranasal desmopressin therapy with overcorrection of severe hyponatremia: A retrospective, propensity score-based, single-center cohort study.
Jingushi N; Tsuzuki S; Fujii K; Uenishi N; Iwata M; Terasawa T
J Crit Care; 2021 Aug; 64():53-61. PubMed ID: 33794467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
